Literature DB >> 33859290

Investigation of type I interferon responses in ANCA-associated vasculitis.

Isabella Batten1, Mark W Robinson2, Arthur White3, Cathal Walsh4, Barbara Fazekas5, Jason Wyse3, Antonia Buettner6, Suzanne D'Arcy6, Emily Greenan7,8, Conor C Murphy7,8, Zoe Wigston9,10, Joan Ní Gabhann-Dromgoole7,11, Edward M Vital9,10, Mark A Little6, Nollaig M Bourke12.   

Abstract

Type I interferon (IFN) dysregulation is a major contributory factor in the development of several autoimmune diseases, termed type I interferonopathies, and is thought to be the pathogenic link with chronic inflammation in these conditions. Anti-neutrophil cytoplasmic antibody (ANCA)-Associated Vasculitis (AAV) is an autoimmune disease characterised by necrotising inflammation of small blood vessels. The underlying biology of AAV is not well understood, however several studies have noted abnormalities in type I IFN responses. We hypothesised that type I IFN responses are systemically dysregulated in AAV, consistent with features of a type I interferonopathy. To investigate this, we measured the expression of seven interferon regulated genes (IRGs) (ISG15, SIGLEC1, STAT1, RSAD2, IFI27, IFI44L and IFIT1) in peripheral blood samples, as well as three type I IFN regulated proteins (CXCL10, MCP-1 and CCL19) in serum samples from AAV patients, healthy controls and disease controls. We found no difference in type I IFN regulated gene or protein expression between AAV patients and healthy controls. Furthermore, IRG and IFN regulated protein expression did not correlate with clinical measurements of disease activity in AAV patients. Thus, we conclude that systemic type I IFN responses are not key drivers of AAV pathogenesis and AAV should not be considered a type I interferonopathy.

Entities:  

Year:  2021        PMID: 33859290     DOI: 10.1038/s41598-021-87760-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  71 in total

1.  Type I interferonopathies: a novel set of inborn errors of immunity.

Authors:  Yanick J Crow
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

2.  Activation of the interferon pathway in peripheral blood of patients with Sjogren's syndrome.

Authors:  Osamu Kimoto; Jin Sawada; Kumiko Shimoyama; Daisuke Suzuki; Satoki Nakamura; Hideharu Hayashi; Noriyoshi Ogawa
Journal:  J Rheumatol       Date:  2010-11-15       Impact factor: 4.666

3.  An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity.

Authors:  Emily C Baechler; Jason W Bauer; Catherine A Slattery; Ward A Ortmann; Karl J Espe; Jill Novitzke; Steven R Ytterberg; Peter K Gregersen; Timothy W Behrens; Ann M Reed
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

4.  The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction.

Authors:  G G Hunder; W P Arend; D A Bloch; L H Calabrese; A S Fauci; J F Fries; R Y Leavitt; J T Lie; R W Lightfoot; A T Masi
Journal:  Arthritis Rheum       Date:  1990-08

Review 5.  Classification of ANCA-associated vasculitis.

Authors:  Irfan Khan; Richard A Watts
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

Review 6.  Dynamic control of type I IFN signalling by an integrated network of negative regulators.

Authors:  Rebecca A Porritt; Paul J Hertzog
Journal:  Trends Immunol       Date:  2015-02-25       Impact factor: 16.687

7.  The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study.

Authors:  Alvise Berti; Divi Cornec; Cynthia S Crowson; Ulrich Specks; Eric L Matteson
Journal:  Arthritis Rheumatol       Date:  2017-11-09       Impact factor: 10.995

8.  Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.

Authors:  Gillian I Rice; Gabriella M A Forte; Marcin Szynkiewicz; Diana S Chase; Alec Aeby; Mohamed S Abdel-Hamid; Sam Ackroyd; Rebecca Allcock; Kathryn M Bailey; Umberto Balottin; Christine Barnerias; Genevieve Bernard; Christine Bodemer; Maria P Botella; Cristina Cereda; Kate E Chandler; Lyvia Dabydeen; Russell C Dale; Corinne De Laet; Christian G E L De Goede; Mireia Del Toro; Laila Effat; Noemi Nunez Enamorado; Elisa Fazzi; Blanca Gener; Madli Haldre; Jean-Pierre S-M Lin; John H Livingston; Charles Marques Lourenco; Wilson Marques; Patrick Oades; Pärt Peterson; Magnhild Rasmussen; Agathe Roubertie; Johanna Loewenstein Schmidt; Stavit A Shalev; Rogelio Simon; Ronen Spiegel; Kathryn J Swoboda; Samia A Temtamy; Grace Vassallo; Catheline N Vilain; Julie Vogt; Vanessa Wermenbol; William P Whitehouse; Doriette Soler; Ivana Olivieri; Simona Orcesi; Mona S Aglan; Maha S Zaki; Ghada M H Abdel-Salam; Adeline Vanderver; Kai Kisand; Flore Rozenberg; Pierre Lebon; Yanick J Crow
Journal:  Lancet Neurol       Date:  2013-10-30       Impact factor: 44.182

9.  Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus.

Authors:  K L Connelly; R Kandane-Rathnayake; M Huq; A Hoi; M Nikpour; E F Morand
Journal:  Sci Rep       Date:  2018-02-19       Impact factor: 4.379

Review 10.  The Dual Nature of Type I and Type II Interferons.

Authors:  Amanda J Lee; Ali A Ashkar
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

View more
  2 in total

Review 1.  Type I Interferon and the Spectrum of Susceptibility to Viral Infection and Autoimmune Disease: A Shared Genomic Signature.

Authors:  Jamie A Sugrue; Nollaig M Bourke; Cliona O'Farrelly
Journal:  Front Immunol       Date:  2021-11-30       Impact factor: 7.561

Review 2.  Graphene-Based Biosensors for Molecular Chronic Inflammatory Disease Biomarker Detection.

Authors:  Isidro Badillo-Ramírez; Yojana J P Carreón; Claudia Rodríguez-Almazán; Claudia M Medina-Durán; Selene R Islas; José M Saniger
Journal:  Biosensors (Basel)       Date:  2022-04-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.